The study involves the enrollment of patients over 2 years of age with a diagnosis of musculoskeletal tumors and an indication for electrochemotherapy, treated at the Rizzoli Orthopaedic Institute in Bologna and followed during outpatient follow-up. Data will be collected from medical records, outpatient reports, and imaging studies including CT, X-ray, MRI, and/or PET.

For the retrospective part of the study, patients treated at the Rizzoli Orthopaedic Institute from 01/01/2024 to the date of approval of this study will be included. For the prospective part, patients meeting the inclusion criteria and treated from the study start date until 31/12/2030 will be enrolled.

Inclusion Criteria:

• Patients of both sexes with a histological diagnosis of a primary musculoskeletal tumor, either benign or malignant, located outside the abdominal cavity (trunk and limbs)

• Indication for electrochemotherapy due to one of the following conditions:

  1. Clinical conditions contraindicating surgery
  2. Tumor not surgically resectable

• Patients treated with electrochemotherapy at the Rizzoli Orthopaedic Institute:

  1. From 01/01/2024 to the date of study approval for the retrospective phase
  2. From the date of study approval to 12/31/2030 for the prospective phase

• Retrospectively treated patients with a minimum follow-up of at least 3 months

• Age ≥ 2 years at the time of treatment

• Availability of clinical and instrumental data

Exclusion Criteria:

• Failure to meet at least one of the inclusion criteria

The study will include patients older than 2 years with a diagnosis of musculoskeletal tumors who are indicated for electrochemotherapy, treated at the Rizzoli Orthopaedic Institute in Bologna and followed during outpatient follow-up. Data will be collected from medical records, outpatient reports, and imaging studies (CT, X-ray, MRI, and/or PET).

The retrospective part will include patients treated at the Rizzoli Orthopaedic Institute from January 1, 2024, to the date of study approval.

The prospective part will enroll patients meeting the inclusion criteria who will be treated from the study start date until December 31, 2030.